glp 1 for non obese people GLP-1 If Not Overweight: Biomarker & Clinical Criteria – PlexusDx GLP-1 receptor agonists | How

Originally approved by the FDA for Type 2 diabetes (Ozempic in 2017) and weight loss (Wegovy in 2021), these medications help users manage obesity by suppressing appetite

DEVOTE landmark safety outcomes trial Tresiba U-100 demonstrated no increased risk of major adverse cardiovascular events (MACE) vs insulin glargine U-100 for adults with type 2 diabetes and ASCVD 2,d The secondary confirmatory endpoint showed Tresiba U-100 also demonstrated statistically significant lower rates of severe hypoglycemic events vs insulin glargine U-100 2,e A flat and stable profile 2-4 Tresiba provides a steady rate of absorption into the bloodstream, giving it a flat and stable profile at steady state

It appears to enhance the fundamental cellular processes of tissue repair, resulting in structurally improved healing rather than just symptomatic relief

M.ShuS.HowsonR.NeupaneR.HayesR

[7] Weight management represents the second major indication